The Most Common Problems in FDA Software Validation & Verification

John E Lincoln Instructor:
John E Lincoln 
Friday, August 26, 2022
10:00 AM PDT | 01:00 PM EDT
90 Minutes
Webinar ID: 500669

More Trainings by this Expert

Price Details
Live Webinar
$149 One Attendee
$299 Corporate Live
Recorded Webinar
$199 One Attendee
$399 Corporate Recorded
Combo Offers
Live + Recorded
$299 $348 Live + Recorded
Corporate (Live + Recorded)
$599 $698 Corporate
(Live + Recorded)

Live: One Dial-in One Attendee

Corporate Live: Any number of participants

Recorded: Access recorded version, only for one participant unlimited viewing for 6 months ( Access information will be emailed 24 hours after the completion of live webinar)

Corporate Recorded: Access recorded version, Any number of participants unlimited viewing for 6 months ( Access information will be emailed 24 hours after the completion of live webinar)

Overview:

This webinar will address the use of the FDA, GAMP, and other applicable industry software validation models, coupled with the ISO 14971 model to structure, run, and document acceptable software validations.

The U.S. FDA has stated that software validation can only be risk-based. This applies to Software:

  • As-Product
  • In-Product
  • In Production and Test Equipment
  • The Quality System
A manufacturer is responsible to identify those risks and take reasonable steps to address them in the software validation process. The FDA, GAMP, and others provide guidance in the methodology and documentation to achieve this. Consideration of the principles in ISO 14971 can assist in providing an acceptable vehicle by which to perform and document risk-based software V&V.

Areas Covered in the Session:
  • Verification or Validation - Current Regulatory Expectations
  • The Project Validation Plan
  • Product Software Validation and Process / Equipment Software Validations - how they differ
  • When and How to Use DQ, IQ, OQ and PQ
  • ISO 14971:2007 Issues
  • GAMP Guidance
  • The 11 Key Elements of the Software V&V Model
  • "White box" and "Black box" Validations
  • 'Real World' Considerations

Who Will Benefit:
  • Senior Management, Project Leaders
  • Internal / External Auditors and/or Consultants
  • Regulatory Affairs
  • Quality Systems Personnel / QAE
  • New product development, Marketing and R&D
  • Software Product and Process / Manufacturing Engineering Staff
  • Document Control


Speaker Profile
John E. Lincoln is a medical device and regulatory affairs consultant. He has helped companies to implement or modify their GMP systems and procedures, product risk management, U.S. FDA responses. In addition, he has successfully designed, written and run all types of process, equipment and software qualifications/validations, which have passed FDA audit or submission scrutiny, and described in peer-reviewed technical articles, and workshops, world wide.

John has also managed pilot production, regulatory affairs, product development/design control, 510(k) submissions, risk management per ISO 14971, and projects; with over 28 years of experience in the FDA-regulated medical products industry - working with start-ups to Fortune 100 companies, including Abbott Laboratories, Hospira, Tyco/Mallinckrodt. He is a graduate of UCLA.


You Recently Viewed

Subscribe to our Newsletter

Subscribe for Compliance Alerts Research Reports Absolutely Free